As of May 04, 2026, Ligand Pharmaceuticals's top three insider holders are John L Higgins (Chief Executive Officer, 417.69K shares), John W Kozarich (Director, 42.25K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| John L Higgins | Chief Executive Officer | 417,695 | 0 | 30 Dec, 2022 |
| Todd C Davis | Chief Executive Officer | 199,381 | 0 | 27 Mar, 2026 |
| Matthew W Foehr | President And Coo | 162,187 | 0 | 03 Nov, 2022 |
| Jason Aryeh | - | 71,323 | 0 | 08 Dec, 2025 |
| Matthew E Korenberg | President Coo | 50,777 | 0 | 24 Sep, 2024 |
| John W Kozarich | - | 42,253 | 0 | 02 Apr, 2026 |
| Andrew Reardon | Clo Secretary | 41,382 | 0 | 02 Apr, 2026 |
| Andrew Reardon | Clo Secretary | 41,382 | 0 | 02 Apr, 2026 |
| Stephen L Sabba | - | 32,793 | 0 | 25 Mar, 2026 |
| Stephen L Sabba | - | 32,793 | 0 | 25 Mar, 2026 |
| John L Lamattina | - | 30,724 | 0 | 31 Mar, 2026 |
| Sunil Patel | - | 28,820 | 0 | 03 Nov, 2022 |
| Sunil Patel | - | 28,820 | 0 | 03 Nov, 2022 |
| Charles S Berkman | Svp, Gen. Counsel Secretary | 23,825 | 0 | 03 Nov, 2022 |
| Octavio Espinoza | Chief Financial Officer | 21,010 | 0 | 13 Mar, 2026 |
| Nancy Ryan Gray | - | 8,094 | 0 | 12 Nov, 2025 |
| Jason Haas | - | 6,606 | 0 | 10 Jun, 2025 |
| Martine Zimmermann | - | 4,443 | 0 | 24 Sep, 2025 |
| Martine Zimmermann | - | 4,443 | 0 | 24 Sep, 2025 |
| Sarah Boyce | - | 2,892 | 0 | 03 Nov, 2022 |
| Jennifer R. Cochran | - | 1,161 | 0 | 03 Nov, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | John W Kozarich | Common Stock | D | 146 | $199.97 | 42,574 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | A | 5,000 | $52.27 | 46,382 | D | M |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | A | 5,000 | $52.27 | 46,382 | D | M |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 460 | $198.85 | 45,922 | D | S |
| 01 Apr, 2026 | John W Kozarich | Common Stock | D | 40 | $201.24 | 42,534 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 460 | $198.85 | 45,922 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 1,302 | $199.72 | 44,620 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 1,302 | $199.72 | 44,620 | D | S |
| 01 Apr, 2026 | John W Kozarich | Common Stock | D | 79 | $202.42 | 42,455 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 1,238 | $200.94 | 43,382 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 1,238 | $200.94 | 43,382 | D | S |
| 01 Apr, 2026 | John W Kozarich | Common Stock | D | 43 | $202.91 | 42,412 | D | S |
| 01 Apr, 2026 | John W Kozarich | Common Stock | D | 159 | $204.26 | 42,253 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 700 | $201.90 | 42,682 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 700 | $201.90 | 42,682 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 963 | $203.22 | 41,719 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 963 | $203.22 | 41,719 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 337 | $204.50 | 41,382 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Common Stock | D | 337 | $204.50 | 41,382 | D | S |
| 01 Apr, 2026 | Andrew Reardon | Employee Stock Option (right to buy) | D | 5,000 | $0.00 | 49,444 | D | M |